Sick notes

13 August 2019 By Ed Cropley Follow @edwardcropley

The World Bank-backed instruments are meant to use private capital to fight disease in poor countries. But their rather random structures create weird incentives for both issuer and buyer. As a way to tackle outbreaks, it’s not obvious they’re better than more direct charity.

This content is for Subscribers only

Context News

World Bank-backed insurance schemes to help poor countries tackle pandemics quickly have not paid out despite more than 1,800 people dying of Ebola in Democratic Republic of Congo over the last year, the second-worst outbreak on record, according to Reuters.

The three-year bonds were set up after the 2013-2016 West African Ebola outbreak that killed 11,300 people. They only pay out when the virus crosses an international border and claims at least 20 lives in each of the two countries.

So far, only two deaths have occurred outside Congo, in neighbouring Uganda. However, the disease has recently reached Goma, a city of 2 million people on the border with Rwanda.

Scientists are also developing drugs to treat Ebola. Two experimental drugs currently under clinical trial in Congo showed survival rates as high as 90%, Reuters reported on Aug. 12.

Context News

So far, only two deaths have occurred outside Congo, in neighbouring Uganda. However, the disease has recently reached Goma, a city of 2 million people on the border with Rwanda.

Scientists are also developing drugs to treat Ebola. Two experimental drugs currently under clinical trial in Congo showed survival rates as high as 90%, Reuters reported on Aug. 12.

Email a friend

Please complete the form below.

Required fields *